Literature DB >> 25815676

Effect of Glucagon-like Peptide-1 on High-Glucose-induced Oxidative Stress and Cell Apoptosis in Human Endothelial Cells and Its Underlying Mechanism.

Rehua Wang1, Lihong Lu, Yansong Guo, Feng Lin, Haifeng Chen, Wei Chen, Minsheng Chen.   

Abstract

Glucagon-like peptide-1 (GLP-1) has been demonstrated to play an important role in type 2 diabetes mellitus, leading to cardiovascular diseases. This study aimed to examine the GLP-1 regulation of high-glucose-induced oxidative stress and cell apoptosis in human umbilical vein endothelial cells (HUVECs) and its underlying mechanism. HUVECs were isolated from healthy umbilical cords and cultured. GLP-1 and the GLP-1R antagonist, exendin (9-39), were used to pretreat the cells. The expression of NADPH oxidase subunits gp91 and p22 messenger RNA was detected by real-time quantitative polymerase chain reaction. Reactive oxygen species production was detected with flow cytometry and fluorescence microscopy. Lucigenin assay was used to measure the NADPH oxidase activity. The terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling assay was used to investigate endothelial cell apoptosis. Apoptosis proteins were detected by immunoblotting. GLP-1 decreased high-glucose-induced oxidative stress, the expression of gp91 and p22phox messenger RNAs, and NADPH oxidase activation. Exendin (9-39) antagonized the effects of GLP-1 on high-glucose-induced oxidative stress. GLP-1 also increased HUVEC's high-glucose-induced proliferation and inhibited apoptosis. GLP-1 inhibited high-glucose-induced oxidative stress and cell apoptosis in HUVECs through GLP-1R-dependent and GLP-1 (9-36)-related pathways. GLP-1 suppressed high-glucose-induced oxidative stress and consequently may have an antiatherosclerosis effect on diabetes mellitus patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25815676     DOI: 10.1097/FJC.0000000000000255

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

Review 1.  Mitophagy in Human Diseases.

Authors:  Laura Doblado; Claudia Lueck; Claudia Rey; Alejandro K Samhan-Arias; Ignacio Prieto; Alessandra Stacchiotti; Maria Monsalve
Journal:  Int J Mol Sci       Date:  2021-04-09       Impact factor: 5.923

2.  The proper concentrations of dextrose and lidocaine in regenerative injection therapy: in vitro study.

Authors:  Min Seok Woo; Jiyoung Park; Seong-Ho Ok; Miyeong Park; Ju-Tae Sohn; Man Seok Cho; Il-Woo Shin; Yeon A Kim
Journal:  Korean J Pain       Date:  2021-01-01

Review 3.  Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity.

Authors:  Nicola Marrano; Giuseppina Biondi; Anna Borrelli; Angelo Cignarelli; Sebastio Perrini; Luigi Laviola; Francesco Giorgino; Annalisa Natalicchio
Journal:  Biomolecules       Date:  2021-02-15

Review 4.  Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease.

Authors:  Sebastian Steven; Thomas Münzel; Andreas Daiber
Journal:  Int J Mol Sci       Date:  2015-08-05       Impact factor: 5.923

5.  Metabolically-inactive glucagon-like peptide-1(9-36)amide confers selective protective actions against post-myocardial infarction remodelling.

Authors:  Emma Robinson; Mitchel Tate; Samuel Lockhart; Claire McPeake; Karla M O'Neill; Kevin S Edgar; Danielle Calderwood; Brian D Green; Barbara J McDermott; David J Grieve
Journal:  Cardiovasc Diabetol       Date:  2016-04-14       Impact factor: 9.951

Review 6.  Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor.

Authors:  Johanna Helmstädter; Karin Keppeler; Leonie Küster; Thomas Münzel; Andreas Daiber; Sebastian Steven
Journal:  Br J Pharmacol       Date:  2021-05-06       Impact factor: 8.739

7.  Protective Role of Glucagon-Like Peptide-1 Against High-Glucose-Induced Endothelial Oxidative Damage.

Authors:  Lixin Guo; Yue Qiao; Lina Zhang; Qi Pan
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.